Frequency Therapeutics Financials
| KRRO Stock | 52.31 1.69 3.34% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.2 | 8.8656 |
|
|
The financial analysis of Frequency Therapeutics is a critical element in measuring its lifeblood. Investors should not minimize Frequency Therapeutics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Frequency | Select Account or Indicator |
Understanding current and past Frequency Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Frequency Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Frequency Therapeutics' assets may result in an increase in income on the income statement.
Frequency Therapeutics Stock Summary
Frequency Therapeutics competes with Air Lease, Mitsubishi UFJ, Presidio Property, Fortress Transp, and SEI Investments. Frequency Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| CUSIP | 35803L108 500946108 |
| Location | Massachusetts; U.S.A |
| Business Address | One Kendall Square, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.korrobio.com |
| Phone | 617 468 1999 |
Frequency Therapeutics Key Financial Ratios
| Return On Equity | -0.75 | ||||
| EBITDA | (80.9 M) | ||||
| Net Income | (81.17 M) | ||||
| Book Value Per Share | 19.28 X | ||||
| Market Capitalization | 490.05 M |
Frequency Therapeutics Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 223.2M | 264.7M | 127.6M | 73.7M | 221.7M | 153.3M | |
| Other Current Liab | 3.4M | 6.7M | 4.2M | 3.2M | 10.2M | 10.7M | |
| Net Debt | (200.2M) | (174.3M) | (37.9M) | (33.2M) | (132.9M) | (126.3M) | |
| Retained Earnings | (68.9M) | (95.4M) | (43.8M) | (101.8M) | (183.0M) | (173.9M) | |
| Accounts Payable | 1.2M | 5.5M | 789K | 2.6M | 7.3M | 7.6M | |
| Cash | 200.2M | 220.3M | 83.5M | 36.3M | 166.2M | 120.5M | |
| Other Current Assets | 3.2M | 4.4M | 1.2M | 1.8M | 6.6M | 6.9M | |
| Total Liab | 55.9M | 72.2M | 169.8M | 172.8M | 51.8M | 49.2M | |
| Total Current Assets | 221.4M | 225.1M | 119.8M | 57.1M | 172.7M | 134.7M | |
| Common Stock | 14K | 31K | 34K | 5K | 8K | 7.2K |
Frequency Therapeutics Key Income Statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 813K | 1.6M | 3.8M | 2.5M | 3.6M | 2.1M | |
| Gross Profit | 12.1M | 35.4M | 10.2M | (2.5M) | (3.6M) | (3.4M) | |
| Other Operating Expenses | 49.6M | 64.5M | 35.5M | 59.0M | 84.5M | 51.6M | |
| Operating Income | (20.7M) | (27.6M) | (35.5M) | (59.0M) | (84.5M) | (80.3M) | |
| Ebit | (20.7M) | (26.5M) | (37.7M) | (59.0M) | (84.5M) | (80.3M) | |
| Research Development | 18.3M | 36.7M | 23.8M | 42.2M | 57.3M | 31.7M | |
| Ebitda | (19.9M) | (24.9M) | (33.9M) | (56.5M) | (80.9M) | (76.9M) | |
| Cost Of Revenue | 16.8M | 1.6M | 3.8M | 2.5M | 3.6M | 4.6M | |
| Total Operating Expenses | 32.8M | 63.0M | 35.5M | 59.0M | 84.5M | 48.5M | |
| Income Before Tax | (18.7M) | (26.5M) | (22.0M) | (58.0M) | (81.1M) | (77.1M) | |
| Total Other Income Expense Net | 1.9M | 1.1M | 13.5M | 976K | 3.4M | 2.6M | |
| Net Income | (18.7M) | (26.5M) | (22.0M) | (58.0M) | (81.2M) | (77.1M) |
Frequency Therapeutics Key Cash Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 158.0M | 20.2M | 44.4M | (42.6M) | 131.6M | 138.2M | |
| Free Cash Flow | 33.2M | (51.9M) | (36.5M) | (58.9M) | (75.1M) | (71.4M) | |
| Change In Working Capital | 48.6M | (30.2M) | 904K | (633K) | 4.3M | 2.7M | |
| Begin Period Cash Flow | 42.2M | 200.2M | 39.7M | 84.0M | 41.5M | 67.9M | |
| Other Cashflows From Financing Activities | (18.3M) | 10.4M | 115.9M | 18K | 70.5M | 74.0M | |
| Depreciation | 813K | 1.6M | 1.6M | 2.5M | 3.6M | 3.8M | |
| Other Non Cash Items | 5.8M | 8.9M | (13.5M) | 1.5M | 3.6M | 3.8M | |
| Capital Expenditures | 1.1M | 6.7M | 4.4M | 5.2M | 7.8M | 4.3M | |
| Total Cash From Operating Activities | 34.2M | (45.2M) | (32.1M) | (53.6M) | (67.3M) | (63.9M) | |
| Net Income | (18.7M) | (26.5M) | (22.0M) | (58.0M) | (81.2M) | (77.1M) | |
| Total Cash From Financing Activities | 142.0M | 56.7M | 115.9M | 18K | 187.8M | 197.1M | |
| End Period Cash Flow | 200.2M | 220.3M | 84.0M | 41.5M | 173.1M | 122.5M |
Frequency Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Frequency Therapeutics's current stock value. Our valuation model uses many indicators to compare Frequency Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Frequency Therapeutics competition to find correlations between indicators driving Frequency Therapeutics's intrinsic value. More Info.Frequency Therapeutics is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . At this time, Frequency Therapeutics' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Frequency Therapeutics' earnings, one of the primary drivers of an investment's value.Frequency Therapeutics Systematic Risk
Frequency Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Frequency Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Frequency Therapeutics correlated with the market. If Beta is less than 0 Frequency Therapeutics generally moves in the opposite direction as compared to the market. If Frequency Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Frequency Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Frequency Therapeutics is generally in the same direction as the market. If Beta > 1 Frequency Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Frequency Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Frequency Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Frequency Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Frequency Therapeutics November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Frequency Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Frequency Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Frequency Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Frequency Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Frequency Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 5.76 | |||
| Information Ratio | 0.0527 | |||
| Maximum Drawdown | 109.21 | |||
| Value At Risk | (8.79) | |||
| Potential Upside | 7.7 |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Frequency Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Frequency Stock, please use our How to Invest in Frequency Therapeutics guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Frequency Therapeutics. If investors know Frequency will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Frequency Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.42) | Return On Assets (0.35) | Return On Equity (0.75) |
The market value of Frequency Therapeutics is measured differently than its book value, which is the value of Frequency that is recorded on the company's balance sheet. Investors also form their own opinion of Frequency Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Frequency Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Frequency Therapeutics' market value can be influenced by many factors that don't directly affect Frequency Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Frequency Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Frequency Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Frequency Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.